Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer

[1]  B. Kong,et al.  Dendritic cells as cancer therapeutics. , 2019, Seminars in cell & developmental biology.

[2]  N. Halama.  The next age of immunotherapy: optimisation, stratification and therapeutic synergies , 2018, British Journal of Cancer.

[3]  Jakob Nikolas Kather,et al.  Genomics and emerging biomarkers for immunotherapy of colorectal cancer. , 2018, Seminars in cancer biology.

[4]  Itai Sharon,et al.  Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT , 2018, Cell.

[5]  Tae Kon Kim,et al.  Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. , 2018, Trends in immunology.

[6]  N. Halama.  Macrophage repolarisation therapy in colorectal cancer , 2018, ESMO Open.

[7]  G. Ji,et al.  Short-chain fatty acids administration is protective in colitis-associated colorectal cancer development. , 2018, The Journal of nutritional biochemistry.

[8]  J. Tabernero,et al.  Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  R. Rajandram,et al.  Strain‐specific probiotic (microbial cell preparation) and omega‐3 fatty acid in modulating quality of life and inflammatory markers in colorectal cancer patients: a randomized controlled trial , 2018, Asia-Pacific journal of clinical oncology.

[10]  J. Wargo,et al.  The gut microbiota influences anticancer immunosurveillance and general health , 2018, Nature Reviews Clinical Oncology.

[11]  Ö. Türeci,et al.  Personalized vaccines for cancer immunotherapy , 2018, Science.

[12]  Constantino Carlos Reyes-Aldasoro,et al.  Large-scale database mining reveals hidden trends and future directions for cancer immunotherapy , 2018, Oncoimmunology.

[13]  U. Vogel,et al.  Meat and fiber intake and interaction with pattern recognition receptors (TLR1, TLR2, TLR4, and TLR10) in relation to colorectal cancer in a Danish prospective, case-cohort study. , 2018, The American journal of clinical nutrition.

[14]  Y. Cong,et al.  CD177+ neutrophils suppress epithelial cell tumourigenesis in colitis-associated cancer and predict good prognosis in colorectal cancer , 2018, Carcinogenesis.

[15]  Patricia M. Santos,et al.  Dendritic Cell–Based Cancer Vaccines , 2018, The Journal of Immunology.

[16]  Y. Lou,et al.  Cancer immunotherapy beyond immune checkpoint inhibitors , 2018, Journal of Hematology & Oncology.

[17]  R. Stupp,et al.  Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer , 2017, Oncoimmunology.

[18]  C. Martinez,et al.  High levels of tumor-associated neutrophils are associated with improved overall survival in patients with stage II colorectal cancer , 2017, PloS one.

[19]  R. Minshall,et al.  ICAM-1 regulates macrophage polarization by suppressing MCP-1 expression via miR-124 upregulation , 2017, Oncotarget.

[20]  A. Forero,et al.  Modulation of antitumor immunity with histone deacetylase inhibitors. , 2017, Immunotherapy.

[21]  Jan Poleszczuk,et al.  In Silico Modeling of Immunotherapy and Stroma-Targeting Therapies in Human Colorectal Cancer. , 2017, Cancer research.

[22]  P. Gao,et al.  The preoperative neutrophil to lymphocyte ratio is a superior indicator of prognosis compared with other inflammatory biomarkers in resectable colorectal cancer , 2017, BMC Cancer.

[23]  M. Zaidi,et al.  TAMeless traitors: macrophages in cancer progression and metastasis , 2017, British Journal of Cancer.

[24]  David A. Drew,et al.  Aspirin exerts high anti-cancer activity in PIK3CA-mutant colon cancer cells , 2017, Oncotarget.

[25]  J. Desai,et al.  Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. , 2017, The Lancet. Oncology.

[26]  H. Roche,et al.  Nutritional modulation of metabolic inflammation. , 2017, Biochemical Society transactions.

[27]  M. Hemann,et al.  Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer , 2017, Cell.

[28]  A. Mantovani,et al.  Tumor-associated macrophages and response to 5-fluorouracil adjuvant therapy in stage III colorectal cancer , 2017, Oncoimmunology.

[29]  P. Ordentlich,et al.  Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma , 2017, Clinical Cancer Research.

[30]  F. Greten,et al.  Card9‐dependent IL‐1β regulates IL‐22 production from group 3 innate lymphoid cells and promotes colitis‐associated cancer , 2017, European journal of immunology.

[31]  G. Botti,et al.  EGFR in Tumor-Associated Myeloid Cells Promotes Development of Colorectal Cancer in Mice and Associates With Outcomes of Patients , 2017, Gastroenterology.

[32]  A. Tolcher,et al.  First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors , 2017, Clinical Cancer Research.

[33]  Miles A. Miller,et al.  In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy , 2017, Science Translational Medicine.

[34]  Levi Garraway,et al.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.

[35]  S. Garattini,et al.  Immunotherapy for colorectal cancer: where are we heading? , 2017, Expert opinion on biological therapy.

[36]  J. Utikal,et al.  CCR5 in recruitment and activation of myeloid-derived suppressor cells in melanoma , 2017, Cancer Immunology, Immunotherapy.

[37]  A. Shilatifard,et al.  Precancer Atlas to Drive Precision Prevention Trials. , 2017, Cancer research.

[38]  G. Kollias,et al.  Mesenchymal Cells in Colon Cancer. , 2017, Gastroenterology.

[39]  Pengyuan Yang,et al.  Quantitative profiling of glycerophospholipids during mouse and human macrophage differentiation using targeted mass spectrometry , 2017, Scientific Reports.

[40]  Yongzhi Yang,et al.  Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-κB, and Up-regulating Expression of MicroRNA-21. , 2017, Gastroenterology.

[41]  D. Wodarz,et al.  Aspirin-Induced Chemoprevention and Response Kinetics Are Enhanced by PIK3CA Mutations in Colorectal Cancer Cells , 2017, Cancer Prevention Research.

[42]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[43]  Yunqiu Wang,et al.  Oxidative stress induced autophagy in cancer associated fibroblast enhances proliferation and metabolism of colorectal cancer cells , 2017, Cell cycle.

[44]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[45]  David A. Drew,et al.  Regular Aspirin Use Associates With Lower Risk of Colorectal Cancers With Low Numbers of Tumor-Infiltrating Lymphocytes. , 2016, Gastroenterology.

[46]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[47]  N. Halama.  CCR5 inhibition in colorectal cancer patients , 2016 .

[48]  B. Chain,et al.  Cell‐type‐specific modulation of innate immune signalling by vitamin D in human mononuclear phagocytes , 2016, Immunology.

[49]  W. Berger,et al.  Fibroblast growth factor receptor 4 induced resistance to radiation therapy in colorectal cancer , 2016, Oncotarget.

[50]  K. Jirström,et al.  Prognostic impact of tumour‐infiltrating B cells and plasma cells in colorectal cancer , 2016, International journal of cancer.

[51]  R. Kalluri.  The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[52]  R. Fletcher.  Review: Aspirin reduces colorectal cancer incidence and mortality in patients at average risk , 2016, Annals of Internal Medicine.

[53]  G. Milligan,et al.  Metabolism meets immunity: The role of free fatty acid receptors in the immune system. , 2016, Biochemical Pharmacology.

[54]  Christopher J Tape,et al.  Systems Biology Analysis of Heterocellular Signaling. , 2016, Trends in biotechnology.

[55]  M. Preusser,et al.  Tumor-infiltrating lymphocyte subsets and tertiary lymphoid structures in pulmonary metastases from colorectal cancer , 2016, Clinical & Experimental Metastasis.

[56]  J. Meyerhardt,et al.  Marine ω-3 polyunsaturated fatty acid intake and survival after colorectal cancer diagnosis , 2016, Gut.

[57]  C. Garlanda,et al.  Occurrence and significance of tumor‐associated neutrophils in patients with colorectal cancer , 2016, International journal of cancer.

[58]  Kathryn J Fowler,et al.  Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. , 2016, The Lancet. Oncology.

[59]  V. Bronte,et al.  Interfering with CCL5/CCR5 at the Tumor-Stroma Interface. , 2016, Cancer cell.

[60]  M. Koch,et al.  Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. , 2016, Cancer cell.

[61]  P. Tassone,et al.  Phase Ib study of poly-epitope peptide vaccination to thymidylate synthase (TSPP) and GOLFIG chemo-immunotherapy for treatment of metastatic colorectal cancer patients , 2016, Oncoimmunology.

[62]  Etienne Becht,et al.  Cancer immune contexture and immunotherapy. , 2016, Current opinion in immunology.

[63]  Crispin J. Miller,et al.  Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation , 2016, Cell.

[64]  Etienne Becht,et al.  Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy , 2016, Clinical Cancer Research.

[65]  Z. Trajanoski,et al.  Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. , 2016, Immunity.

[66]  M. Belvin,et al.  MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. , 2016, Immunity.

[67]  M. Cobleigh,et al.  Mutations in PIK3CA sensitize breast cancer cells to physiologic levels of aspirin , 2016, Breast Cancer Research and Treatment.

[68]  Y. Ichinose,et al.  Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma. , 2016, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[69]  Yin Cao,et al.  Aspirin and colorectal cancer: the promise of precision chemoprevention , 2016, Nature Reviews Cancer.

[70]  A. Ribas,et al.  Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? , 2016, Seminars in immunology.

[71]  V. Steele,et al.  Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. , 2016, Seminars in oncology.

[72]  G. Jan,et al.  The probiotic Propionibacterium freudenreichii as a new adjuvant for TRAIL-based therapy in colorectal cancer , 2016, Oncotarget.

[73]  Avrum Spira,et al.  Transforming Cancer Prevention through Precision Medicine and Immune-oncology , 2016, Cancer Prevention Research.

[74]  Lewis L. Lanier,et al.  NK cells and cancer: you can teach innate cells new tricks , 2015, Nature Reviews Cancer.

[75]  F. Ginhoux,et al.  Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota , 2015, Science.

[76]  D. Aust,et al.  Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983. , 2015, European journal of cancer.

[77]  Mervin Chávez-Castillo,et al.  Macrophage Heterogeneity and Plasticity: Impact of Macrophage Biomarkers on Atherosclerosis , 2015, Scientifica.

[78]  Fiona Powrie,et al.  Emerging cytokine networks in colorectal cancer , 2015, Nature Reviews Immunology.

[79]  Y. Yamashita,et al.  Impact of perioperative probiotic treatment for surgical site infections in patients with colorectal cancer. , 2015, Experimental and therapeutic medicine.

[80]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[81]  H. Lenz,et al.  Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[82]  Lon Smith,et al.  Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors , 2015, Clinical Cancer Research.

[83]  Brian Ruffell,et al.  Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.

[84]  P. Allavena,et al.  The interaction of anticancer therapies with tumor-associated macrophages , 2015, The Journal of experimental medicine.

[85]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[86]  A. Dalgleish.  Rationale for combining immunotherapy with chemotherapy. , 2015, Immunotherapy.

[87]  A. Mantovani,et al.  Tertiary Lymphoid Tissue in the Tumor Microenvironment: From Its Occurrence to Immunotherapeutic Implications , 2015, International reviews of immunology.

[88]  Y. Akagi,et al.  Personalized peptide vaccination for advanced colorectal cancer , 2015, Oncoimmunology.

[89]  A. Barzi,et al.  Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with locoregional gastric cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[90]  H. Hurwitz,et al.  Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). , 2015 .

[91]  E. Giovannucci,et al.  Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status , 2015, Gut.

[92]  J. Hackney,et al.  The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. , 2014, Cancer cell.

[93]  Axel Hoos,et al.  Classification of current anticancer immunotherapies , 2014, Oncotarget.

[94]  D. Morse,et al.  The Role of Toll-Like Receptors in Colorectal Cancer Progression: Evidence for Epithelial to Leucocytic Transition , 2014, Front. Immunol..

[95]  R. Xavier,et al.  Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity , 2014, Science.

[96]  G. Trinchieri,et al.  Harnessing the intestinal microbiome for optimal therapeutic immunomodulation. , 2014, Cancer research.

[97]  P. Allavena,et al.  Pharmacological modulation of monocytes and macrophages. , 2014, Current opinion in pharmacology.

[98]  G. Cline,et al.  Functional polarization of tumour-associated macrophages by tumour-derived lactic acid , 2014, Nature.

[99]  J. Blay,et al.  Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. , 2014, Cancer cell.

[100]  H. Nielsen,et al.  Urokinase-type plasminogen activator receptor (uPAR) on tumor-associated macrophages is a marker of poor prognosis in colorectal cancer , 2014, Cancer medicine.

[101]  Will Liao,et al.  The cellular and molecular origin of tumor-associated macrophages , 2014, Science.

[102]  G. Trinchieri,et al.  Gut microbiome and anticancer immune response: really hot Sh*t! , 2014, Cell Death and Differentiation.

[103]  Alberto Martin,et al.  The multifaceted role of the intestinal microbiota in colon cancer. , 2014, Molecular cell.

[104]  Tom C. Freeman,et al.  Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation , 2014, Immunity.

[105]  P. Allavena,et al.  Occurrence of Tertiary Lymphoid Tissue Is Associated with T-Cell Infiltration and Predicts Better Prognosis in Early-Stage Colorectal Cancers , 2014, Clinical Cancer Research.

[106]  P. Tassone,et al.  Gemcitabine, Oxaliplatin, Levofolinate, 5-Fluorouracil, Granulocyte-Macrophage Colony-Stimulating Factor, and Interleukin-2 (GOLFIG) Versus FOLFOX Chemotherapy in Metastatic Colorectal Cancer Patients: The GOLFIG-2 Multicentric Open-label Randomized Phase III Trial , 2014, Journal of immunotherapy.

[107]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[108]  K. Schäkel,et al.  Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy. , 2013, Cancer cell.

[109]  D. Olive,et al.  When breast cancer cells start to fend the educational process of NK cells off , 2013, Oncoimmunology.

[110]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[111]  J. Talmadge,et al.  History of myeloid-derived suppressor cells , 2013, Nature Reviews Cancer.

[112]  L. Galluzzi,et al.  Decoding cell death signals in liver inflammation. , 2013, Journal of hepatology.

[113]  Jérôme Galon,et al.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. , 2013, Immunity.

[114]  Peter Schirmacher,et al.  Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue , 2013, Cancer Immunology, Immunotherapy.

[115]  J. Blay,et al.  Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. , 2013, Cancer research.

[116]  C. von Kalle,et al.  Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine. , 2013, Human gene therapy.

[117]  N. Halama,et al.  Hepatic metastases of colorectal cancer are rather homogeneous but differ from primary lesions in terms of immune cell infiltration , 2013, Oncoimmunology.

[118]  M. Zucchetti,et al.  Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.

[119]  D. Koller,et al.  Conservation and divergence in the transcriptional programs of the human and mouse immune systems , 2013, Proceedings of the National Academy of Sciences.

[120]  A. Palucka,et al.  Neutralizing Tumor-Promoting Chronic Inflammation: A Magic Bullet? , 2013, Science.

[121]  A. Cerwenka,et al.  Tumor-Infiltrating Monocytic Myeloid-Derived Suppressor Cells Mediate CCR5-Dependent Recruitment of Regulatory T Cells Favoring Tumor Growth , 2012, The Journal of Immunology.

[122]  Wilfrid Boireau,et al.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth , 2012, Nature Medicine.

[123]  C. Datz,et al.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.

[124]  R. Palmqvist,et al.  The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal Cancer , 2012, PloS one.

[125]  V. Pascual,et al.  Macrophages induce differentiation of plasma cells through CXCL10/IP-10 , 2012, The Journal of experimental medicine.

[126]  M. Mallmann,et al.  High-Resolution Transcriptome of Human Macrophages , 2012, PloS one.

[127]  S. Jalkanen,et al.  Type and location of tumor‐infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients , 2012, International journal of cancer.

[128]  M. Hornef,et al.  Innate immune signalling at the intestinal epithelium in homeostasis and disease , 2012, EMBO reports.

[129]  N. Halama,et al.  Sequential metastases of colorectal cancer , 2012, Oncoimmunology.

[130]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[131]  M. Kinouchi,et al.  Infiltration of CD40-positive tumor-associated macrophages indicates a favorable prognosis in colorectal cancer patients. , 2012, Hepato-gastroenterology.

[132]  F. Bertucci,et al.  “Stealth” tumors , 2012, Oncoimmunology.

[133]  N. Goldman,et al.  Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages , 2012, Proceedings of the National Academy of Sciences.

[134]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[135]  A. Mantovani,et al.  Cancer-related inflammation: common themes and therapeutic opportunities. , 2012, Seminars in cancer biology.

[136]  F. Bertucci,et al.  Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. , 2011, Cancer research.

[137]  Axel Benner,et al.  Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. , 2011, Cancer research.

[138]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[139]  M. Kinouchi,et al.  Infiltration of CD14-positive macrophages at the invasive front indicates a favorable prognosis in colorectal cancer patients with lymph node metastasis. , 2011, Hepato-gastroenterology.

[140]  M. Merino,et al.  T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[141]  M. Koch,et al.  Natural Killer Cells are Scarce in Colorectal Carcinoma Tissue Despite High Levels of Chemokines and Cytokines , 2011, Clinical Cancer Research.

[142]  M. Kloor,et al.  Quantification of prognostic immune cell markers in colorectal cancer using whole slide imaging tumor maps. , 2010, Analytical and quantitative cytology and histology.

[143]  A. Algra,et al.  Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.

[144]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[145]  S. Burgdorf.  Dendritic cell vaccination of patients with metastatic colorectal cancer. , 2010, Danish medical bulletin.

[146]  L. Saltz,et al.  Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[147]  Israel Lowy,et al.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[148]  E. Tartour,et al.  Immune infiltration in human tumors: a prognostic factor that should not be ignored , 2010, Oncogene.

[149]  Niels Grabe,et al.  Estimation of Immune Cell Densities in Immune Cell Conglomerates: An Approach for High-Throughput Quantification , 2009, PloS one.

[150]  A. Poustka,et al.  Down‐regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells , 2009, International journal of cancer.

[151]  S. Ferrini,et al.  IL‐8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer , 2009, International journal of cancer.

[152]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  L. Ellis,et al.  Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[154]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[155]  P. Rothwell,et al.  Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies , 2007, The Lancet.

[156]  D. Middleton,et al.  Human NK cell education by inhibitory receptors for MHC class I. , 2006, Immunity.

[157]  Ruslan Medzhitov,et al.  Role of toll-like receptors in spontaneous commensal-dependent colitis. , 2006, Immunity.

[158]  E. Thiel,et al.  Clinical and Immunologic Responses to Active Specific Cancer Vaccines in Human Colorectal Cancer , 2006, Clinical Cancer Research.

[159]  P. Nelson,et al.  Cytotoxic Markers and Frequency Predict Functional Capacity of Natural Killer Cells Infiltrating Renal Cell Carcinoma , 2006, Clinical Cancer Research.

[160]  J. Brayer,et al.  Arginase I Production in the Tumor Microenvironment by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-Specific T-Cell Responses , 2004, Cancer Research.

[161]  Ruslan Medzhitov,et al.  Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis , 2004, Cell.

[162]  Timothy R Church,et al.  Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. , 2003, Journal of the National Cancer Institute.

[163]  C. Falk,et al.  Renal cell carcinoma‐infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes , 2003, International journal of cancer.

[164]  K Eichmann,et al.  Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. , 1999, Journal of immunology.

[165]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[166]  H. Morselt,et al.  The effect of liver macrophages on in vitro cytolytic activity of 5FU and FUdR on colon carcinoma cells: evidence of macrophage activation. , 1992, International journal of immunopharmacology.

[167]  J. Zucman‐Rossi,et al.  Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. , 2016, Advances in immunology.

[168]  J. Vansteenkiste,et al.  Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[169]  I. Endo,et al.  Low Infiltration of Peritumoral Regulatory T Cells Predicts Worse Outcome Following Resection of Colorectal Liver Metastases , 2014, Annals of Surgical Oncology.

[170]  M. Koch,et al.  T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer , 2012, Cancer Immunology, Immunotherapy.

[171]  M. Kloor,et al.  The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. , 2009, Cancer immunity.

[172]  R. Salter,et al.  Dendritic cells in cancer , 2009 .

[173]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[174]  On Chemotherapy. , 1924, Canadian Medical Association journal.